COMENTARIOS A ARTÍCULOS DE INVESTIGACIÓN CLÍNICA Y BÁSICA
Inmunogenicidad cruzada: anticuerpos para infliximab en pacientes con enfermedad inflamatoria intestinal tratados con Remicade reconocen similarmente al biosimilar Remsima
Cross-immunogenicity: Antibodies to infliximab in Remicade-treated patients with inflammatory bowel disease similarly recognise the biosimilar Remsima
J.R. Márquez Velásquez
Instituto de Coloproctología ICO, Clínica Las Américas, Medellín, Colombia
Leído
4649
Vecesse ha leído el artículo
1193
Total PDF
3456
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 15 | 6 | 21 |
| 2025 11 | 76 | 20 | 96 |
| 2025 10 | 42 | 5 | 47 |
| 2025 9 | 47 | 20 | 67 |
| 2025 8 | 48 | 14 | 62 |
| 2025 7 | 43 | 6 | 49 |
| 2025 6 | 59 | 8 | 67 |
| 2025 5 | 50 | 3 | 53 |
| 2025 4 | 51 | 3 | 54 |
| 2025 3 | 65 | 10 | 75 |
| 2025 2 | 35 | 3 | 38 |
| 2025 1 | 44 | 4 | 48 |
| 2024 12 | 28 | 2 | 30 |
| 2024 11 | 43 | 6 | 49 |
| 2024 10 | 50 | 9 | 59 |
| 2024 9 | 45 | 15 | 60 |
| 2024 8 | 30 | 7 | 37 |
| 2024 7 | 33 | 9 | 42 |
| 2024 6 | 37 | 18 | 55 |
| 2024 5 | 32 | 21 | 53 |
| 2024 4 | 27 | 12 | 39 |
| 2024 3 | 34 | 9 | 43 |
| 2024 2 | 53 | 26 | 79 |
| 2024 1 | 49 | 40 | 89 |
| 2023 12 | 39 | 19 | 58 |
| 2023 11 | 53 | 39 | 92 |
| 2023 10 | 61 | 20 | 81 |
| 2023 9 | 55 | 4 | 59 |
| 2023 8 | 31 | 2 | 33 |
| 2023 7 | 36 | 8 | 44 |
| 2023 6 | 34 | 2 | 36 |
| 2023 5 | 47 | 16 | 63 |
| 2023 4 | 37 | 14 | 51 |
| 2023 3 | 47 | 10 | 57 |
| 2023 2 | 26 | 7 | 33 |
| 2022 1 | 25 | 18 | 43 |
| 2022 12 | 41 | 17 | 58 |
| 2022 11 | 40 | 13 | 53 |
| 2022 10 | 49 | 22 | 71 |
| 2022 9 | 26 | 21 | 47 |
| 2022 8 | 32 | 8 | 40 |
| 2022 7 | 19 | 7 | 26 |
| 2022 6 | 20 | 7 | 27 |
| 2022 5 | 29 | 11 | 40 |
| 2022 4 | 25 | 18 | 43 |
| 2022 3 | 43 | 22 | 65 |
| 2022 2 | 24 | 4 | 28 |
| 2021 1 | 45 | 14 | 59 |
| 2021 12 | 34 | 19 | 53 |
| 2021 11 | 24 | 18 | 42 |
| 2021 10 | 46 | 13 | 59 |
| 2021 9 | 25 | 17 | 42 |
| 2021 8 | 27 | 15 | 42 |
| 2021 7 | 44 | 12 | 56 |
| 2021 6 | 33 | 13 | 46 |
| 2021 5 | 37 | 10 | 47 |
| 2021 4 | 71 | 45 | 116 |
| 2021 3 | 54 | 17 | 71 |
| 2021 2 | 49 | 15 | 64 |
| 2020 1 | 44 | 13 | 57 |
| 2020 12 | 49 | 12 | 61 |
| 2020 11 | 69 | 16 | 85 |
| 2020 10 | 24 | 12 | 36 |
| 2020 9 | 38 | 9 | 47 |
| 2020 8 | 37 | 7 | 44 |
| 2020 7 | 32 | 3 | 35 |
| 2020 6 | 21 | 6 | 27 |
| 2020 5 | 24 | 5 | 29 |
| 2020 4 | 16 | 4 | 20 |
| 2020 3 | 30 | 7 | 37 |
| 2020 2 | 35 | 5 | 40 |
| 2020 1 | 28 | 10 | 38 |
| 2019 12 | 27 | 12 | 39 |
| 2019 11 | 32 | 8 | 40 |
| 2019 10 | 39 | 12 | 51 |
| 2019 9 | 32 | 3 | 35 |
| 2019 8 | 29 | 8 | 37 |
| 2019 7 | 35 | 14 | 49 |
| 2019 6 | 55 | 24 | 79 |
| 2019 5 | 133 | 76 | 209 |
| 2019 4 | 53 | 39 | 92 |
| 2019 3 | 19 | 8 | 27 |
| 2019 2 | 21 | 7 | 28 |
| 2019 1 | 29 | 8 | 37 |
| 2018 12 | 9 | 2 | 11 |
| 2018 11 | 16 | 14 | 30 |
| 2018 10 | 17 | 5 | 22 |
| 2018 9 | 7 | 8 | 15 |
| 2018 8 | 4 | 4 | 8 |
| 2018 7 | 7 | 2 | 9 |
| 2018 6 | 15 | 4 | 19 |
| 2018 5 | 12 | 7 | 19 |
| 2018 4 | 13 | 8 | 21 |
| 2018 3 | 9 | 0 | 9 |
| 2018 2 | 7 | 2 | 9 |
| 2018 1 | 9 | 2 | 11 |
| 2016 1 | 1 | 0 | 1 |
| 2016 10 | 2 | 0 | 2 |
| 2016 5 | 1 | 0 | 1 |
| 2016 4 | 6 | 9 | 15 |
| 2016 3 | 6 | 5 | 11 |
Mostrar todo
